EHTH · Ehealth, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88.02M | - | $53.87M | $60.78M | $113.12M | - | $58.41M | $65.86M | $92.96M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | $36.73M | - | ($3.78M) | $18.89M | $29.45M | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $15.51M | - | $21.93M | $21.58M | $17.31M | - | $20.30M | $22.40M | $19.62M | - |
| Total Operating Expenses | $90.90M | - | $95.39M | $83.83M | $108.32M | - | $101.61M | $93.81M | $110.88M | - |
| D&A | $490.0K | - | - | - | $471.0K | - | $3.83M | $4.28M | $4.41M | - |
| Operating Income | ($2.88M) | - | ($41.52M) | ($23.04M) | $4.80M | - | ($43.20M) | ($27.96M) | ($17.91M) | - |
| Interest Expense | $4.04M | - | $2.38M | $2.35M | $2.81M | - | $2.86M | $2.85M | $2.81M | - |
| Income Tax | ($1.36M) | - | ($11.24M) | ($6.65M) | $1.78M | - | ($1.89M) | ($505.0K) | ($1.34M) | - |
| Net Income | ($4.71M) | - | ($31.69M) | ($17.40M) | $1.95M | - | ($42.47M) | ($27.97M) | ($16.98M) | - |
| EPS - Basic | ($0.58) | - | ($1.46) | ($0.98) | ($0.33) | - | ($1.83) | ($1.33) | ($0.96) | - |
| EPS - Diluted | ($0.58) | - | ($1.46) | ($0.98) | ($0.33) | - | ($1.83) | ($1.33) | ($0.96) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $75.11M | $73.72M | $63.09M | $65.92M | $121.09M | $39.20M | $64.03M | $126.34M | $174.99M | $115.72M |
| Accounts Receivable | $1.54M | $7.69M | $1.85M | $1.86M | $3.39M | $16.81M | $5.86M | $1.18M | $1.41M | $3.99M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.59M | $28.32M | $6.21M | $5.75M | $7.35M | $23.45M | $5.41M | $4.96M | $6.29M | $7.20M |
| Current Assets | $336.61M | $334.35M | $302.87M | $328.17M | $369.44M | $354.48M | $340.87M | $355.85M | $404.36M | $382.35M |
| Total Assets | $1.20B | $1.26B | $1.05B | $1.08B | $1.14B | $1.16B | $1.00B | $1.04B | $1.10B | $1.11B |
| Current Liabilities | $44.35M | $99.07M | $51.24M | $110.20M | $143.35M | $96.01M | $53.85M | $116.30M | $146.04M | $78.54M |
| Long-term Debt | $113.76M | $112.95M | $69.42M | $0 | $0 | $68.46M | $69.16M | $0 | $0 | $67.75M |
| Total Liabilities | $231.46M | $288.82M | $162.95M | $165.88M | $207.55M | $229.49M | $175.52M | $172.70M | $205.42M | $209.26M |
| Stockholders' Equity | $575.73M | $591.60M | $514.17M | $554.92M | $581.62M | $588.43M | $499.35M | $548.85M | $582.80M | $606.03M |
| Retained Earnings | $12.01M | $30.12M | ($43.81M) | ($12.12M) | $5.27M | $15.25M | ($113.36M) | ($59.41M) | ($20.43M) | $7.28M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $35.77M | - | - | - | $77.12M | - | - | - | $70.76M | - |
| Investing Cash Flow | ($34.36M) | - | - | - | $5.47M | - | - | - | ($10.29M) | - |
| Financing Cash Flow | ($160.0K) | - | - | - | ($699.0K) | - | - | - | ($1.26M) | - |
| CapEx | $155.0K | - | - | - | $308.0K | - | - | - | $204.0K | - |
| Free Cash Flow | $35.61M | - | - | - | $76.81M | - | - | - | $70.56M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 41.7% | - | -7.0% | 31.1% | 26.0% | - | - | - | - | - |
| Operating margin | -3.3% | - | -77.1% | -37.9% | 4.2% | - | -74.0% | -42.5% | -19.3% | - |
| EBITDA margin | -2.7% | - | - | - | 4.7% | - | -67.4% | -36.0% | -14.5% | - |
| Net margin | -5.4% | - | -58.8% | -28.6% | 1.7% | - | -72.7% | -42.5% | -18.3% | - |
| Free cash flow margin | 40.5% | - | - | - | 67.9% | - | - | - | 75.9% | - |
| FCF / Net income | -7.55 | - | - | - | 39.39 | - | - | - | -4.15 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 17.6% | - | 40.7% | 35.5% | 15.3% | - | 34.7% | 34.0% | 21.1% | - |
| Effective tax rate | - | - | - | - | 47.7% | - | - | - | - | - |
| Return on assets | -0.4% | - | -3.0% | -1.6% | 0.2% | - | -4.2% | -2.7% | -1.6% | - |
| Return on equity | -0.8% | - | -6.2% | -3.1% | 0.3% | - | -8.5% | -5.1% | -2.9% | - |
| Return on invested capital | -0.3% | - | -5.6% | -3.3% | 0.4% | - | -6.0% | -4.0% | -2.4% | - |
| Liquidity | ||||||||||
| Current ratio | 7.59 | 3.37 | 5.91 | 2.98 | 2.58 | 3.69 | 6.33 | 3.06 | 2.77 | 4.87 |
| Quick ratio | 7.59 | 3.37 | 5.91 | 2.98 | 2.58 | 3.69 | 6.33 | 3.06 | 2.77 | 4.87 |
| Cash ratio | 1.69 | 0.74 | 1.23 | 0.60 | 0.84 | 0.41 | 1.19 | 1.09 | 1.20 | 1.47 |
| Leverage | ||||||||||
| Debt / Equity | 0.20 | 0.19 | 0.14 | 0.00 | 0.00 | 0.12 | 0.14 | 0.00 | 0.00 | 0.11 |
| Debt / Assets | 0.09 | 0.09 | 0.07 | 0.00 | 0.00 | 0.06 | 0.07 | 0.00 | 0.00 | 0.06 |
| Debt / EBITDA | - | - | - | - | 0.00 | - | - | - | - | - |
| Interest coverage | -0.7x | - | -17.4x | -9.8x | 1.7x | - | -15.1x | -9.8x | -6.4x | - |
| Equity multiplier | 2.09 | 2.13 | 2.04 | 1.95 | 1.96 | 1.96 | 2.01 | 1.89 | 1.88 | 1.84 |
| Liabilities / Assets | 0.19 | 0.23 | 0.16 | 0.15 | 0.18 | 0.20 | 0.18 | 0.17 | 0.19 | 0.19 |
| Efficiency | ||||||||||
| Asset turnover | 0.07 | - | 0.05 | 0.06 | 0.10 | - | 0.06 | 0.06 | 0.08 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 6d | - | 13d | 11d | 11d | - | 37d | 7d | 6d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.1x | - | 0.3x | 0.2x | 0.3x | - | 0.2x | 0.2x | 0.3x | - |
| P / S | 0.5x | - | 2.5x | 2.2x | 1.8x | - | 2.1x | 2.0x | 1.9x | - |
| EV / EBITDA | - | - | - | - | 15.0x | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -22.2% | - | -7.8% | -7.7% | 21.7% | - | -9.7% | -1.4% | 26.1% | - |
| Revenue CAGR (3y) | 6.1% | - | 0.3% | 6.4% | 2.4% | - | -3.0% | -12.0% | -11.5% | - |
| Revenue CAGR (5y) | -8.1% | - | -10.6% | -7.3% | 1.2% | - | 7.5% | 15.1% | 16.6% | - |
| Gross profit growth (YoY) | 24.7% | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | 3.9% | 17.6% | - | - | -9.7% | -6.9% | 21.8% | - |
| Net income growth (YoY) | - | - | 25.4% | 37.8% | - | - | -14.7% | -19.0% | 14.6% | - |
| EPS growth (YoY) | -75.8% | - | 20.2% | 26.3% | 65.6% | - | -8.9% | -12.7% | 5.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -53.6% | - | - | - | 8.9% | - | - | - | 16.2% | - |
| FCF CAGR (5y) | -2.7% | - | - | - | 64.4% | - | - | - | 44.4% | - |
| Book value growth (YoY) | -1.0% | 0.5% | 3.0% | 1.1% | -0.2% | -2.9% | -10.8% | -8.7% | -7.2% | -6.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$554.01M totalMedicare Segment$531.21M · 95.9%
Employer And Individual Segment$22.80M · 4.1%
Product / service
$1.49B totalCommission$497.95M · 33.4%
Commission Members Approved During Current Period$433.20M · 29.1%
Medicare$421.81M · 28.3%
Product And Service Other$56.05M · 3.8%
Commission Members Approved In Prior Periods$42.96M · 2.9%
Ancillaries$12.16M · 0.8%
Small Business$11.10M · 0.7%
Commission Revenue From Renewals$8.86M · 0.6%
Commission Bonus$2.96M · 0.2%
Individualand Family$1.90M · 0.1%
Peer comparison
Same SIC group: Insurance Agents, Brokers & Service
Comparing eHealth against the 5 most active filers in the same SIC group.